

CITATION REPORT

List of articles citing

Long-term follow-up of patients with nonalcoholic fatty liver

DOI: 10.1016/j.cgh.2008.11.005

Clinical Gastroenterology and Hepatology, 2009, 7, 234-8.

Source: <https://exaly.com/paper-pdf/46892252/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
614	Use of statins in patients with liver disease. 2009 , 11, 272-8		38
613	Non-alcoholic fatty liver disease from pathogenesis to management: an update. 2010 , 11, 430-45		128
612	Outcomes of patients with non-alcoholic fatty liver disease. 2009 , 51, 594-595		
611	Non-invasive assessment and quantification of liver steatosis by ultrasound, computed tomography and magnetic resonance. 2009 , 51, 433-45		556
610	Non-alcoholic fatty liver disease: is bariatric surgery the answer?. 2009 , 13, 689-710		45
609	Nonalcoholic fatty liver disease: a practical approach to evaluation and management. 2009 , 13, 249-66		48
608	NASH and HCC. 2009 , 13, 631-47		101
607	Epidemiology and natural history of non-alcoholic steatohepatitis. 2009 , 13, 511-31		284
606	Non-Alcoholic Fatty Liver Disease. 2010 , 19, 36-50		4
605	Non-alcoholic fatty liver disease: the hepatic consequence of obesity and the metabolic syndrome. 2010 , 69, 211-20		156
604	Unravelling the pathogenesis of fatty liver disease: patatin-like phospholipase domain-containing 3 protein. 2010 , 21, 247-52		62
603	Hepatic gene expression of Caucasian and African-American patients with obesity-related non-alcoholic fatty liver disease. 2010 , 20, 640-50		40
602	Transient elastography in nonalcoholic fatty liver disease: making sense of echoes. 2010 , 51, 370-2		9
601	Thiazolidinedione therapy for nonalcoholic steatohepatitis: go, stop, or proceed with caution?. 2010 , 51, 366-9		7
600	Cigarette smoking exacerbates nonalcoholic fatty liver disease in obese rats. 2010 , 51, 1567-76		90
599	Long-term mortality in nonalcoholic fatty liver disease: is liver histology of any prognostic significance?. 2010 , 51, 373-5		153
598	Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. 2010 , 51, 1820-32		957

597	[Nonalcoholic fatty liver disease]. 2010 , 56, 6-14	7
596	Histopathology of nonalcoholic fatty liver disease. 2010 , 16, 5286-96	262
595	The natural history of non-alcoholic fatty liver disease. 2010 , 28, 162-8	126
594	Hepatocellular carcinoma and non-alcoholic fatty liver disease: from a clinical to a molecular association. 2010 , 16, 741-52	52
593	Nonalcoholic steatohepatitis: risk factors and diagnosis. 2010 , 4, 623-35	38
592	Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. 2010 , 363, 1185; author reply 1186	38
591	[Non-alcoholic fatty liver disease]. 2010 , 30, 413-20	1
590	Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. 2010 , 363, 1341-50	1353
589	Phosphoproteomic biomarkers predicting histologic nonalcoholic steatohepatitis and fibrosis. 2010 , 9, 3218-24	18
588	Treatment options for nonalcoholic fatty liver disease. 2010 , 3, 121-37	103
587	The 148M allele of the PNPLA3 gene is associated with indices of liver damage early in life. 2010 , 53, 335-8	121
586	Hepatocellular ballooning in NASH. 2010 , 53, 719-23	138
585	Enfermedad del hígado graso no alcohólico y riesgo cardiovascular. 2010 , 22, 259-271	
584	Lower circulating levels of dehydroepiandrosterone, independent of insulin resistance, is an important determinant of severity of non-alcoholic steatohepatitis in Japanese patients. 2010 , 40, 901-10	18
583	Antisense technology to lower LDL cholesterol. 2010 , 375, 959-61	11
582	Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis. 2010 , 376, 1916-22	459
581	Gastrointestinal system and obesity. 2010 , 26, 625-7	5
580	Pathology of nonalcoholic fatty liver disease. 2010 , 7, 195-203	350

579	Oxidative stress is activated by free fatty acids in cultured human hepatocytes. 2011 , 9, 397-401	38
578	Nonalcoholic Fatty Liver Disease. 2011 , 868-907	1
577	Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. 2011 , 140, 124-31	1517
576	Do patients with nonalcoholic fatty liver disease die from their heart?. 2011 , 35, 163-5	4
575	Inflammation in nonalcoholic steatohepatitis. 2011 , 5, 189-200	60
574	Non-alcoholic fatty liver disease. 2011 , 48, 97-113	216
573	Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. 2011 , 43, 617-49	894
572	Comparison of NAFLD fibrosis score and BARD score in predicting fibrosis in nonalcoholic fatty liver disease. 2011 , 54, 160-3	57
571	Splenectomy reduces fibrosis and preneoplastic lesions with increased triglycerides and essential fatty acids in rat liver cirrhosis induced by a choline-deficient L-amino acid-defined diet. 2011 , 41, 463-74	9
570	Update on fatty liver disease and steatohepatitis. 2011 , 18, 294-300	43
569	Non-Alcoholic Fatty Liver Disease and Nutrition. 2011 , 546-567	6
568	Nonalcoholic fatty liver disease across ethno-racial groups: do Asian-American adults represent a new at-risk population?. 2011 , 26, 501-9	17
567	Postprandial insulin secretion pattern is associated with histological severity in non-alcoholic fatty liver disease patients without prior known diabetes mellitus. 2011 , 26, 517-22	32
566	Systematic review: association of polycystic ovary syndrome with metabolic syndrome and non-alcoholic fatty liver disease. 2011 , 33, 801-14	87
565	Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. 2011 , 34, 274-85	2020
564	Nonalcoholic steatohepatitis and increased risk of chronic kidney disease. 2011 , 60, 735-9	108
563	Treatment of atherogenic liver based on the pathogenesis of nonalcoholic fatty liver disease: a novel approach to reduce cardiovascular risk?. 2011 , 42, 337-53	29
562	Acute and Chronic Hepatitis. 2011 , 811-828.e5	

561	Nonalcoholic fatty liver disease and diabetes mellitus: pathogenesis and treatment. 2011 , 7, 456-65	227
560	Nonalcoholic fatty liver disease and the coronary artery disease. 2011 , 56, 35-45	56
559	A simple clinical scoring system using ferritin, fasting insulin, and type IV collagen 7S for predicting steatohepatitis in nonalcoholic fatty liver disease. 2011 , 46, 257-68	158
558	Prevalence, gender, ethnic variations, and prognosis of NASH. 2011 , 46 Suppl 1, 63-9	177
557	The pathological role of visceral fat accumulation in steatosis, inflammation, and progression of nonalcoholic fatty liver disease. 2011 , 46 Suppl 1, 70-8	49
556	A biomarker panel for non-alcoholic steatohepatitis (NASH) and NASH-related fibrosis. 2011 , 21, 431-9	117
555	Association of obestatin, ghrelin, and inflammatory cytokines in obese patients with non-alcoholic fatty liver disease. 2011 , 21, 1750-7	36
554	Pathologic criteria for nonalcoholic steatohepatitis: interprotocol agreement and ability to predict liver-related mortality. 2011 , 53, 1874-82	422
553	Endpoints and clinical trial design for nonalcoholic steatohepatitis. 2011 , 54, 344-53	463
552	Mortality in nonalcoholic fatty liver disease: clues from the Cremona study. 2011 , 54, 6-8	7
551	Changes in hepatitis A and B vaccination rates in adult patients with chronic liver diseases and diabetes in the U.S. population. 2011 , 54, 1167-78	26
550	Pentoxifylline for steatohepatitis: magic bullet or smoking gun?. 2011 , 54, 1496-9	3
549	Non-alcoholic fatty liver disease (NAFLD): why you should care, when you should worry, what you should do. 2011 , 27, 419-24	22
548	Novel treatment strategies for patients with nonalcoholic fatty liver disease. 2011 , 1, 229-239	5
547	Non-alcoholic fatty liver disease: what's new under the microscope?. 2011 , 60, 1152-8	23
546	Nonalcoholic fatty liver disease: a review of the spectrum of disease, diagnosis, and therapy. 2011 , 26, 565-76	78
545	Coronary artery disease and cardiovascular outcomes in patients with non-alcoholic fatty liver disease. 2011 , 60, 1721-7	205
544	Mechanisms and implications of age-related changes in the liver: nonalcoholic Fatty liver disease in the elderly. 2011 , 2011, 831536	62

543	Diagnosis and management of chronic liver disease in older people. 2011 , 21, 1-15	7
542	Nonalcoholic fatty liver disease is associated with atherosclerosis in middle-aged and elderly Chinese. 2012 , 32, 2321-6	79
541	PNPLA3 is regulated by glucose in human hepatocytes, and its I148M mutant slows down triglyceride hydrolysis. 2012 , 302, E1063-9	71
540	Prevalence of non-alcoholic fatty liver disease and advanced fibrosis in Hong Kong Chinese: a population study using proton-magnetic resonance spectroscopy and transient elastography. 2012 , 61, 409-15	328
539	Predictors of impaired glucose regulation in patients with non-alcoholic fatty liver disease. 2012 , 2012, 351974	11
538	Hypercoagulation and thrombophilia in nonalcoholic fatty liver disease: mechanisms, human evidence, therapeutic implications, and preventive implications. 2012 , 32, 39-48	31
537	Large-scale long-term follow-up study of Japanese patients with non-alcoholic Fatty liver disease for the onset of hepatocellular carcinoma. 2012 , 107, 253-61	173
536	Non-invasive determination of hepatic steatosis by acoustic structure quantification from ultrasound echo amplitude. 2012 , 18, 3889-95	49
535	Dyslipidemia in patients with nonalcoholic fatty liver disease. 2012 , 32, 22-9	135
534	Nonalcoholic fatty liver disease in lean individuals in the United States. 2012 , 91, 319-327	319
533	Liver transplantation for nonalcoholic steatohepatitis: the new epidemic. 2012 , 256, 624-33	178
532	Hepatocellular carcinoma in nonalcoholic fatty liver cirrhosis and alcoholic cirrhosis: risk factor analysis in liver transplant recipients. 2012 , 24, 840-8	31
531	Fatty liver: a link to cardiovascular disease--its natural history, pathogenesis, and treatment. 2012 , 8, 21-5	11
530	Cardiovascular disease and nonalcoholic fatty liver disease: does histologic severity matter?. 2012 , 46, 427-30	25
529	Non-alcoholic fatty liver disease in type 2 diabetes: pathogenesis and treatment options. 2012 , 10, 162-72	42
528	The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. 2012 , 142, 1592-609	1208
527	Hepatocellular carcinoma in non-alcoholic steatohepatitis: Growing evidence of an epidemic?. 2012 , 42, 1-14	86
526	Pathophysiological analysis of nonalcoholic fatty liver disease by evaluation of fatty liver changes and blood flow using xenon computed tomography: can early-stage nonalcoholic steatohepatitis be distinguished from simple steatosis?. 2012 , 47, 1238-47	19

525	Safety of cardiac surgery in cirrhotic patients: going to the heart of the matter. <i>Clinical Gastroenterology and Hepatology</i> , 2012 , 10, 450-1	6.9	1
524	Independent association between nonalcoholic fatty liver disease and cardiovascular disease in the US population. <i>Clinical Gastroenterology and Hepatology</i> , 2012 , 10, 646-50	6.9	223
523	Identification of liver proteins altered by type 2 diabetes mellitus in obese subjects. 2012 , 32, 951-61		37
522	Presence and severity of non-alcoholic fatty liver disease in a large prospective primary care cohort. 2012 , 56, 234-40		213
521	Hepatocellular carcinoma in non-alcoholic fatty liver disease: an emerging menace. 2012 , 56, 1384-91		606
520	Natural history of nonalcoholic fatty liver disease. 2012 , 1, 112-113		5
519	Nonalcoholic fatty liver disease: Indications for liver biopsy and noninvasive biomarkers. 2012 , 1, 104-107		21
518	Hepatic steatosis and steatohepatitis in human immunodeficiency virus/hepatitis C virus-coinfected patients. 2012 , 56, 1261-70		30
517	Non-alcoholic fatty liver disease. 2012 , 4, 266-80		38
516	The cardiovascular link to nonalcoholic fatty liver disease: a critical analysis. 2012 , 16, 599-613		23
515	Increased risk of cardiovascular disease and chronic kidney disease in NAFLD. 2012 , 9, 372-81		90
514	The relevance of liver histology to predicting clinically meaningful outcomes in nonalcoholic steatohepatitis. 2012 , 16, 487-504		37
513	Non-alcoholic Fatty Liver Disease: East Versus West. 2012 , 2, 122-34		29
512	Epidemiology and Natural History of Non-alcoholic Fatty Liver Disease. 2012 , 2, 135-44		51
511	HCC and NASH: how strong is the clinical demonstration?. 2012 , 36, 202-8		32
510	The diagnosis and management of non-alcoholic fatty liver disease: Practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. 2012 , 107, 811-26		279
509	Traditional Chinese medicines benefit to nonalcoholic fatty liver disease: a systematic review and meta-analysis. 2012 , 39, 9715-22		58
508	Validation of the FIB4 index in a Japanese nonalcoholic fatty liver disease population. 2012 , 12, 2		210

507	The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. 2012 , 55, 2005-23	2285
506	The spontaneous course of liver enzymes and its correlation in nonalcoholic fatty liver disease. 2012 , 57, 1925-31	23
505	Natural course of nonalcoholic fatty liver disease in southern China: a prospective cohort study. 2012 , 13, 153-60	59
504	Nonalcoholic fatty liver disease: the hepatic metabolic syndrome. 2012 , 24, 345-51	6
503	Usefulness of Technetium-99 m-2-methoxy-isobutyl-isonitrile liver scintigraphy for evaluating disease activity of non-alcoholic fatty liver disease. 2012 , 42, 273-9	9
502	Association of coffee and caffeine consumption with fatty liver disease, nonalcoholic steatohepatitis, and degree of hepatic fibrosis. 2012 , 55, 429-36	219
501	Treatment of nonalcoholic fatty liver disease in adults and children: a closer look at the arsenal. 2012 , 47, 29-36	5
500	Predictors of all-cause mortality and liver-related mortality in patients with non-alcoholic fatty liver disease (NAFLD). 2013 , 58, 3017-23	177
499	Fatty liver index correlates with non-alcoholic fatty liver disease, but not with newly diagnosed coronary artery atherosclerotic disease in Chinese patients. 2013 , 13, 110	21
498	B cell-activating factor is associated with the histological severity of nonalcoholic fatty liver disease. 2013 , 7, 539-47	27
497	NAFLD fibrosis score: is it ready for wider use in clinical practice and for clinical trials?. 2013 , 145, 717-9	8
496	Vitamin E and changes in serum alanine aminotransferase levels in patients with non-alcoholic steatohepatitis. 2013 , 38, 134-43	125
495	Epigenetic regulation of hepatocellular carcinoma in non-alcoholic fatty liver disease. 2013 , 23, 471-82	66
494	Nonalcoholic fatty liver disease: an emerging threat to obese and diabetic individuals. 2013 , 1281, 106-22	183
493	Non-alcoholic fatty liver disease and cardiovascular risk. 2013 , 167, 1109-17	64
492	Relationship between hepatocellular carcinoma, metabolic syndrome and non-alcoholic fatty liver disease: which clinical arguments?. 2013 , 74, 115-20	8
491	Association of Sleep Disorders with Nonalcoholic Fatty Liver Disease (NAFLD): A Population-based Study. 2013 , 3, 181-5	26
490	Association of coronary artery calcification with hepatic steatosis in asymptomatic individuals. 2013 , 88, 1259-65	40

489	Severity of non-alcoholic steatohepatitis is associated with substitution of adipose tissue in skeletal muscle. 2013 , 28, 1507-14	75
488	Die nichtalkoholische Steatohepatitis als viszerale Manifestation des metabolischen Syndroms. 2013 , 8, 517-524	
487	Nonalcoholic fatty liver disease and the metabolic syndrome: clinical implications and treatment. 2013 , 28, 40-51	46
486	Dietary fructose enhances the incidence of precancerous hepatocytes induced by administration of diethylnitrosamine in rat. 2013 , 18, 54	20
485	The global NAFLD epidemic. 2013 , 10, 686-90	1078
484	Heterogeneity of fibrosis patterns in non-alcoholic fatty liver disease supports the presence of multiple fibrogenic pathways. 2013 , 33, 624-32	40
483	Liver stiffness measurements in patients with different stages of nonalcoholic fatty liver disease: diagnostic performance and clinicopathological correlation. 2013 , 58, 265-74	64
482	Validation of terminal peptide of procollagen III for the detection and assessment of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease. 2013 , 57, 103-11	81
481	In patients with non-alcoholic fatty liver disease, metabolically abnormal individuals are at a higher risk for mortality while metabolically normal individuals are not. 2013 , 62, 352-60	112
480	[Risk factors associated with non-alcoholic fatty liver disease: a case-control study]. 2013 , 141, 233-9	5
479	Nonalcoholic Steatohepatitis: Diagnostic Challenges. 2013 , 6, 227-57	2
478	From NAFLD in clinical practice to answers from guidelines. 2013 , 59, 859-71	249
477	Serum Eglutamyltranspeptidase predicts all-cause, cardiovascular and liver mortality in older adults. 2013 , 3, 4-11	26
476	External validation of the fatty liver index for identifying nonalcoholic fatty liver disease in a population-based study. <i>Clinical Gastroenterology and Hepatology</i> , 2013 , 11, 1201-4	6.9 128
475	Lomitapide for homozygous familial hypercholesterolaemia. 2013 , 381, 7-8	22
474	Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. 2013 , 10, 330-44	1022
473	Nonalcoholic fatty liver disease: current issues and novel treatment approaches. 2013 , 73, 1-14	123
472	Anthropometric and clinical factors associated with mortality in subjects with nonalcoholic fatty liver disease. 2013 , 58, 1132-40	43

471	Omega-3 fatty acids for treatment of non-alcoholic fatty liver disease: design and rationale of randomized controlled trial. 2013 , 13, 85	48
470	Hard clinical outcomes in patients with NAFLD. 2013 , 7 Suppl 2, 790-9	7
469	Interaction of type 2 diabetes and nonalcoholic fatty liver disease. 2013 , 7, 405-7	8
468	Insulin-like growth factor-I, inflammatory proteins, and fibrosis in subjects with nonalcoholic fatty liver disease. 2013 , 98, E304-8	48
467	Diabetes and nonalcoholic Fatty liver disease: a pathogenic duo. 2013 , 34, 84-129	157
466	Diet Quality. 2013 ,	1
465	Hepatic fatty acid trafficking: multiple forks in the road. 2013 , 4, 697-710	74
464	Pediatric Nonalcoholic Fatty Liver Disease. 2013 , 28, 335-355	1
463	Third-generation inhibitor for the renin-angiotensin system: Can it strongly protect against progression of hepatic fibrosis in non-alcoholic steatohepatitis?. 2013 , 43, 1127-9	
462	Emerging drugs for non-alcoholic steatohepatitis. 2013 , 18, 279-90	12
461	Nonalcoholic fatty liver in nondiabetic patients with acute coronary syndromes. 2013 , 43, 429-38	31
460	The Natural History of NAFLD. 2013 , 37-45	0
459	Current management of patients with nonalcoholic fatty liver disease. 2013 , 8, 549-558	1
458	Characteristics and diagnosis of NAFLD/NASH. 2013 , 28 Suppl 4, 64-70	141
457	Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States. 2013 , 57, 1357-65	459
456	NAFLD fibrosis score: a prognostic predictor for mortality and liver complications among NAFLD patients. 2013 , 19, 1219-29	89
455	Glycemic variability is an independent predictive factor for development of hepatic fibrosis in nonalcoholic fatty liver disease. 2013 , 8, e76161	32
454	Cardiovascular and Systemic Risk in Nonalcoholic Fatty Liver Disease - Atherosclerosis as a Major Player in the Natural Course of NAFLD. 2013 , 19, 5177-5192	80

453	Comparison of fatty liver index with noninvasive methods for steatosis detection and quantification. 2013 , 19, 57-64	77
452	Non-alcoholic fatty liver disease and diabetes: from physiopathological interplay to diagnosis and treatment. 2014 , 20, 8377-92	53
451	Association between noninvasive fibrosis markers and cardio-vascular organ damage among adults with hepatic steatosis. 2014 , 9, e104941	23
450	Dietary fructose reduction improves markers of cardiovascular disease risk in Hispanic-American adolescents with NAFLD. 2014 , 6, 3187-201	85
449	Nonalcoholic fatty liver disease and vascular disease: state-of-the-art. 2014 , 20, 13306-24	135
448	Definition, Pathogenesis, and Natural Progress of Non-alcoholic Fatty Liver Disease. 2014 , 15, 65	2
447	Carotid Artery Intima-Media Thickness and Nonalcoholic Fatty Liver Disease Severity. 2014 , 02,	
446	Non-alcoholic fatty liver disease: what the clinician needs to know. 2014 , 20, 12956-80	117
445	Clinical differences between alcoholic liver disease and nonalcoholic fatty liver disease. 2014 , 20, 8393-406	71
444	Survey of health status, nutrition and geography of food selection of chronic liver disease patients. 2014 , 13, 533-540	15
443	Triglyceride is strongly associated with nonalcoholic fatty liver disease among markers of hyperlipidemia and diabetes. 2014 , 2, 633-636	61
442	Liver biopsy at the time of bariatric surgery: a benefit for patients and the medical community. 2014 , 34, 1-6	11
441	Non-alcoholic fatty liver disease in patients with diabetes mellitus. 2014 , 9, 503-514	
440	Markers of endothelial dysfunction in patients with non-alcoholic fatty liver disease and coronary artery disease. 2014 , 29, 1528-34	12
439	Nonalcoholic fatty liver disease: intravoxel incoherent motion diffusion-weighted MR imaging-an experimental study in a rabbit model. 2014 , 270, 131-40	49
438	Prevalence and natural history of histologically proven chronic liver disease in a longitudinal cohort of patients with type 1 diabetes. 2014 , 60, 158-68	27
437	Increased risk of cirrhosis and hepatocellular cancer during long-term follow-up of patients with biopsy-proven NAFLD. 2014 , 49, 1111-8	28
436	The pathogenesis of hepatocellular carcinoma. 2014 , 32, 545-53	40

435	Nonalcoholic steatohepatitis associated with metabolic syndrome: relationship to insulin resistance and liver histology. 2014 , 48, 883-8	20
434	Epidemiology of Nonalcoholic Fatty Liver Disease. 2014 , 86, 399	1
433	The interactions of nonalcoholic fatty liver disease and cardiovascular diseases. 2014 , 18, 233-48	15
432	Type 2 diabetes mellitus is associated with the fibrosis severity in patients with nonalcoholic fatty liver disease in a large retrospective cohort of Japanese patients. 2014 , 49, 1477-84	87
431	New and Improved Imaging Modalities for NAFLD. 2014 , 13, 88-96	1
430	Coffee consumption in NAFLD patients with lower insulin resistance is associated with lower risk of severe fibrosis. 2014 , 34, 1250-8	62
429	Integrative Weight Management. 2014 ,	2
428	Nonalcoholic Fatty Liver Disease. 2014 , 145-169	1
427	Hepatic gene expression profiles differentiate presymptomatic patients with mild versus severe nonalcoholic fatty liver disease. 2014 , 59, 471-82	188
426	Extrahepatic complications of nonalcoholic fatty liver disease. 2014 , 59, 1174-97	350
425	Efficacy of ezetimibe for reducing serum low-density lipoprotein cholesterol levels resistant to lifestyle intervention in patients with non-alcoholic fatty liver disease. 2014 , 44, 812-7	8
424	Non-alcoholic fatty liver disease (NAFLD) fibrosis score predicts 6.6-year overall mortality of Chinese patients with NAFLD. 2014 , 41, 643-9	23
423	Pathological features of fatty liver disease. 2014 , 147, 754-64	226
422	Alcohol consumption and recurrence of non-B or non-C hepatocellular carcinoma after hepatectomy: a propensity score analysis. 2014 , 49, 1352-61	11
421	Non-alcoholic fatty liver disease, obesity and the metabolic syndrome. 2014 , 28, 637-53	218
420	Obesity-associated mechanisms of hepatocarcinogenesis. 2014 , 63, 607-17	121
419	Non Alcoholic Fatty Liver: Should We Care?. 2014 , 8, 1	1
418	Cirrhosis and end-stage chronic liver disease: The changing scenes on etiopathogenesis. 2014 , 4, 62-77	

417	Management of dyslipidemia as a cardiovascular risk factor in individuals with nonalcoholic fatty liver disease. <i>Clinical Gastroenterology and Hepatology</i> , 2014 , 12, 1077-84; quiz e59-60	6.9	27
416	Diastolic dysfunction and cardiovascular risk in old subjects: possible association with NAFLD?. 2014 , 58, 188-95		8
415	No significant effects of ethyl-eicosapentanoic acid on histologic features of nonalcoholic steatohepatitis in a phase 2 trial. 2014 , 147, 377-84.e1		212
414	NAFLD leads to liver cancer: do we have sufficient evidence?. 2014 , 345, 230-4		44
413	Ectopic fat, insulin resistance, and nonalcoholic fatty liver disease: implications for cardiovascular disease. 2014 , 34, 1155-61		99
412	Lipid lowering in liver and chronic kidney disease. 2014 , 28, 339-52		7
411	Risk of cardiovascular, cardiac and arrhythmic complications in patients with non-alcoholic fatty liver disease. 2014 , 20, 1724-45		160
410	Limitations of liver biopsy and non-invasive diagnostic tests for the diagnosis of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. 2014 , 20, 475-85		296
409	Liver Transplantation for NASH-Related Cirrhosis. 2015 , 3, 1		
408	Future watch: Evolving trends in the management of nonalcoholic steatohepatitis. 2015 , 5, 139-141		
407	Serum alanine aminotransferase predicts the histological course of non-alcoholic steatohepatitis in Japanese patients. 2015 , 45, E53-61		32
406	[Mechanism Analysis and Prevention of Pathogenesis of Nonalcoholic Steatohepatitis]. 2015 , 70, 197-204		5
405	Clinical impact of alcohol-related cirrhosis in the next decade: estimates based on current epidemiological trends in the United States. 2015 , 39, 2085-94		57
404	Practical approach to non-alcoholic fatty liver disease in patients with diabetes. 2015 , 32, 1121-33		10
403	Predictors of malignancies and overall mortality in Japanese patients with biopsy-proven non-alcoholic fatty liver disease. 2015 , 45, 728-38		24
402	Prevalence and risk factors for biopsy-proven non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in a prospective cohort of adult patients with gallstones. 2015 , 35, 1983-91		17
401	Liver fibrosis in non-alcoholic fatty liver disease - diagnostic challenge with prognostic significance. 2015 , 21, 11077-87		82
400	Dysregulated Hepatic Methionine Metabolism Drives Homocysteine Elevation in Diet-Induced Nonalcoholic Fatty Liver Disease. 2015 , 10, e0136822		61

399	Nonalcoholic Steatohepatitis: Involvement of the Telomerase and Proinflammatory Mediators. 2015 , 2015, 850246	7
398	Correlation between serum cytokeratin-18 and the progression or regression of non-alcoholic fatty liver disease. 2015 , 14, 837-44	21
397	Extragastric manifestations of Helicobacter pylori infection: Possible role of bacterium in liver and pancreas diseases. 2015 , 7, 2968-79	38
396	Non-Alcoholic Fatty Liver Disease in Patients with Diabetes Mellitus: A Clinician's Perspective. 2015 , 01,	2
395	Long-Term Outcomes of Nonalcoholic Fatty Liver Disease. 2015 , 14, 69-76	8
394	Amount of hepatic fat predicts cardiovascular risk independent of insulin resistance among Hispanic-American adolescents. 2015 , 14, 39	28
393	Cost-utility analysis of nonalcoholic steatohepatitis screening. 2015 , 25, 3282-94	35
392	High-throughput sequencing reveals altered expression of hepatic microRNAs in nonalcoholic fatty liver disease-related fibrosis. 2015 , 166, 304-14	55
391	Increased Plasma Levels of Asymmetric Dimethylarginine in Nonalcoholic Fatty Liver Disease: Relation With Insulin Resistance, Inflammation, and Liver Histology. 2015 , 63, 871-7	10
390	Challenges and opportunities in drug and biomarker development for nonalcoholic steatohepatitis: findings and recommendations from an American Association for the Study of Liver Diseases-U.S. Food and Drug Administration Joint Workshop. 2015 , 61, 1392-405	223
389	Beneficial effects of neomangiferin on high fat diet-induced nonalcoholic fatty liver disease in rats. 2015 , 25, 218-28	22
388	The Progression of Non-alcoholic Fatty Liver Disease and Lifestyle Intervention in Older Adults. 2015 , 85-97	1
387	Ezetimibe for the treatment of nonalcoholic steatohepatitis: assessment by novel magnetic resonance imaging and magnetic resonance elastography in a randomized trial (MOZART trial). 2015 , 61, 1239-50	233
386	Helicobacter pylori infection might have a potential role in hepatocyte ballooning in nonalcoholic fatty liver disease. 2015 , 50, 996-1004	41
385	Clinical features of hepatocellular carcinoma associated with nonalcoholic fatty liver disease: a review of human studies. 2015 , 8, 1-9	53
384	Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. 2015 , 50, 364-77	138
383	Cardiac structure and function are altered in type 2 diabetes and non-alcoholic fatty liver disease and associate with glycemic control. 2015 , 14, 23	28
382	Phytosterols increase circulating endothelial progenitor cells and insulin-like growth factor-1 levels in patients with nonalcoholic fatty liver disease: A randomized crossover study. 2015 , 13, 148-157	6

381	FXR agonists as therapeutic agents for non-alcoholic fatty liver disease. 2015 , 17, 500	64
380	Lipid Management. 2015 ,	1
379	Potential epigenetic mechanism in non-alcoholic Fatty liver disease. 2015 , 16, 5161-79	62
378	Advanced fibrosis associates with atherosclerosis in subjects with nonalcoholic fatty liver disease. 2015 , 241, 145-50	50
377	Nonalcoholic Fatty Liver Disease Review: Diagnosis, Treatment, and Outcomes. <i>Clinical Gastroenterology and Hepatology</i> , 2015 , 13, 2062-70	6.9 197
376	Maltitol Prevents the Progression of Fatty Liver Degeneration in Mice Fed High-Fat Diets. 2015 , 18, 1081-7	4
375	Nonalcoholic Fatty liver disease, diabetes, obesity, and hepatocellular carcinoma. 2015 , 19, 361-79	117
374	Management and diagnosis of fatty liver disease. 2015 , 9, 671-83	7
373	NAFLD: a multisystem disease. 2015 , 62, S47-64	1286
372	Clinical Model for NASH and Advanced Fibrosis in Adult Patients With Diabetes and NAFLD: Guidelines for Referral in NAFLD. 2015 , 38, 1347-55	121
371	The use of omega-3 Fatty acids in nonalcoholic Fatty liver disease: the end of the road or a new beginning?. 2015 , 166, 1335-7	4
370	Non-Alcoholic Fatty Liver Disease (NAFLD): The Lipid Disease of the Liver and the Effect of Statins. 2015 , 149-173	1
369	Statins and the liver. 2015 , 33, 257-65	7
368	Nonalcoholic fatty liver disease as a potential risk factor of cardiovascular disease. 2015 , 27, 193-9	40
367	Xanthine oxidase in non-alcoholic fatty liver disease and hyperuricemia: One stone hits two birds. 2015 , 62, 1412-9	87
366	Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. 2015 , 45, 363-77	122
365	Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. 2015 , 61, 1547-54	1158
364	Systemic Complications of Nonalcoholic Fatty Liver Disease: When the Liver Is Not an Innocent Bystander. 2015 , 35, 236-49	54

363	Epidemiology and Natural History of Nonalcoholic Fatty Liver Disease. 2015 , 35, 221-35	235
362	Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management. 2015 , 62, 1148-55	626
361	Non-Alcoholic Steatohepatitis: Limited Available Treatment Options but Promising Drugs in Development and Recent Progress Towards a Regulatory Approval Pathway. 2015 , 75, 1373-92	50
360	Nonalcoholic Fatty Liver Disease-Related Hepatocellular Carcinoma: A Problem of Growing Magnitude. 2015 , 35, 304-17	45
359	Nonalcoholic fatty liver disease - current status and future directions. 2015 , 16, 541-57	61
358	Non-alcoholic fatty liver disease following liver transplantation: a clinical review. 2015 , 29, 728-37	12
357	Diagnosis and Assessment of NAFLD: Definitions and Histopathological Classification. 2015 , 35, 207-20	75
356	Epidemiological modifiers of non-alcoholic fatty liver disease: Focus on high-risk groups. 2015 , 47, 997-1006	279
355	Mechanistic link between nonalcoholic fatty liver disease and cardiometabolic disorders. 2015 , 201, 408-14	44
354	Caring for children with NAFLD and navigating their care into adulthood. 2015 , 12, 617-28	16
353	Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. <i>Clinical Gastroenterology and Hepatology</i> , 2015 , 13, 643-54.e1-9; quiz e39-40	6.9 804
352	Diagnosis and classification of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: Current concepts and remaining challenges. 2015 , 45, 20-8	60
351	Diagnosis and management of cardiovascular risk in nonalcoholic fatty liver disease. 2015 , 9, 629-50	57
350	Lower levels of insulin-like growth factor-1 standard deviation score are associated with histological severity of non-alcoholic fatty liver disease. 2015 , 45, 771-81	46
349	[Non-alcoholic fatty liver disease and hepatocellular carcinoma - 2016]. 2016 , 157, 987-94	2
348	Nonalcoholic fatty liver disease as a multi-systemic disease. 2016 , 22, 4079-90	68
347	. 2016 ,	2
346	Non-Alcoholic Fatty Liver Disease and Extra-Hepatic Cancers. 2016 , 17,	111

345	Epicardial Adipose Tissue (EAT) Thickness Is Associated with Cardiovascular and Liver Damage in Nonalcoholic Fatty Liver Disease. 2016 , 11, e0162473	34
344	Fatty liver is associated with an increased risk of diabetes and cardiovascular disease - Evidence from three different disease models: NAFLD, HCV and HIV. 2016 , 22, 9674-9693	69
343	Nonalcoholic fatty liver disease - A multisystem disease?. 2016 , 22, 9488-9505	103
342	Liver transplantation for nonalcoholic steatohepatitis in young patients. 2016 , 29, 418-24	50
341	The association between non-alcoholic steatohepatitis and intrahepatic cholangiocarcinoma: A hospital based case-control study. 2016 , 113, 779-83	22
340	Hypertension and non-alcoholic fatty liver disease proven by transient elastography. 2016 , 46, 1304-1310	16
339	Influence of the rs738409 polymorphism in patatin-like phospholipase 3 on the treatment efficacy of non-alcoholic fatty liver disease with type 2 diabetes mellitus. 2016 , 46, E146-53	16
338	Association of coronary artery calcification with liver fibrosis in Japanese patients with non-alcoholic fatty liver disease. 2016 , 46, 1107-1117	11
337	Is there a mechanistic link between hepatic steatosis and cardiac rather than liver events?. 2016 , 103-110	
336	Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis. 2016 , 65, 589-600	640
335	Natural History of Nonalcoholic Fatty Liver Disease. 2016 , 61, 1226-33	80
334	Epidemiological Trends in NASH as a Cause for Liver Transplant. 2016 , 15, 67-74	5
333	Nonalcoholic Fatty Liver Disease: Prognosis and Progression of Disease. 2016 , 15, 117-124	1
332	Noninvasive Markers of Fibrosis and Inflammation in Nonalcoholic Fatty Liver Disease. 2016 , 15, 86-95	16
331	Non-alcoholic fatty liver disease fibrosis score and preclinical vascular damage in morbidly obese patients. 2016 , 48, 904-8	4
330	Fatty liver is an independent predictor of early carotid atherosclerosis. 2016 , 65, 95-102	67
329	Cardiovascular Risk Reduction in Patients with Nonalcoholic Fatty Liver Disease: The Potential Role of Ezetimibe. 2016 , 61, 3425-3435	12
328	[An Overview of NAFLD/NASH in Japan]. 2016 , 136, 565-72	7

327	Non-alcoholic fatty liver disease. 2016 , 1-7	1
326	Evaluating the Relationship Between Metabolic Syndrome and Liver Biopsy-Proven Non-Alcoholic Steatohepatitis in China: A Multicenter Cross-Sectional Study Design. 2016 , 33, 2069-2081	9
325	Prohibitin-induced, obesity-associated insulin resistance and accompanying low-grade inflammation causes NASH and HCC. 2016 , 6, 23608	25
324	Nonalcoholic Fatty Liver Disease: Pathophysiology and Management. 2016 , 45, 639-652	117
323	Nonalcoholic Fatty Liver Disease and Mean Platelet Volume: A Systemic Review and Meta-analysis. 2016 , 50, 69-74	21
322	The Liver in Systemic Diseases. 2016 ,	1
321	Association between non-alcoholic hepatic steatosis and hyper reactive blood pressure response on the exercise treadmill test. 2016 , 109, 531-7	1
320	Global Epidemiology and Risk Factors for Nonalcoholic Fatty Liver Disease. 2016 , 21-40	1
319	Fatty acid metabolism is altered in non-alcoholic steatohepatitis independent of obesity. 2016 , 65, 655-666	57
318	Alcoholic and Non-Alcoholic Fatty Liver Disease. 2016 ,	3
317	The role of immune mechanisms in alcoholic and nonalcoholic steatohepatitis: a 2015 update. 2016 , 10, 243-53	24
316	Comparison of the Phenotype and Approach to Pediatric vs Adult Patients With Nonalcoholic Fatty Liver Disease. 2016 , 150, 1798-810	84
315	Statins and the Liver. 2016 , 45, 117-28	7
314	Cardiovascular Disease and Myocardial Abnormalities in Nonalcoholic Fatty Liver Disease. 2016 , 61, 1246-67	75
313	Progression of carotid vascular damage and cardiovascular events in non-alcoholic fatty liver disease patients compared to the general population during 10 years of follow-up. 2016 , 246, 208-13	61
312	Screening for Nonalcoholic Steatohepatitis in Individuals with Type 2 Diabetes: A Cost-Effectiveness Analysis. 2016 , 61, 2108-17	44
311	Diagnostic Considerations and Clinical End Points for Nonalcoholic Steatohepatitis. 2016 , 211-221	
310	Contribution of Alcoholic and Nonalcoholic Fatty Liver Disease to the Burden of Liver-Related Morbidity and Mortality. 2016 , 150, 1778-85	173

309	Pathogenesis of Nonalcoholic Steatohepatitis. 2016 , 150, 1769-77		217
308	Quantification of liver fat: A comprehensive review. 2016 , 71, 174-89		47
307	Non-alcoholic fatty liver disease and liver transplantation. 2016 , 65, 1208-23		35
306	Liver Transplantation for Alcoholic and Nonalcoholic Fatty Liver Disease: Pretransplant Selection and Posttransplant Management. 2016 , 150, 1849-62		17
305	Using an Electronic Medical Records Database to Identify Non-Traditional Cardiovascular Risk Factors in Nonalcoholic Fatty Liver Disease. 2016 , 111, 671-6		17
304	Current and Emerging Therapies for Nonalcoholic Fatty Liver Disease. 2016 , 313-337		
303	Effects of Alcohol Consumption on Hepatocarcinogenesis in Japanese Patients With Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2016 , 14, 597-605	6.9	18
302	Non-alcoholic fatty liver disease and risk of cardiovascular disease. 2016 , 65, 1136-50		152
301	Obesity. 2016 ,		4
300	Hepatic FDG uptake is associated with future cardiovascular events in asymptomatic individuals with non-alcoholic fatty liver disease. 2017 , 24, 892-899		10
299	Association between volume and glucose metabolism of abdominal adipose tissue in healthy population. 2017 , 11, 133-143		12
298	Derivation and validation of a scoring system for predicting nonalcoholic steatohepatitis in Taiwanese patients with severe obesity. 2017 , 13, 686-692		10
297	Associations of the fatty liver and hepatic steatosis indices with risk of cardiovascular disease: Interrelationship with age. 2017 , 466, 54-60		17
296	A multi-component classifier for nonalcoholic fatty liver disease (NAFLD) based on genomic, proteomic, and phenomic data domains. 2017 , 7, 43238		27
295	The occurrence of hepatocellular carcinoma in different risk stratifications of clinically noncirrhotic nonalcoholic fatty liver disease. 2017 , 141, 1307-1314		42
294	Role of folate in nonalcoholic fatty liver disease. 2017 , 95, 1141-1148		34
293	Diagnostic accuracy of serum alanine aminotransferase as biomarker for nonalcoholic fatty liver disease and insulin resistance in healthy subjects, using 3T MR spectroscopy. 2017 , 96, e6770		26
292	Long-Term Outcomes of Nonalcoholic Fatty Liver Disease: From Nonalcoholic Steatohepatitis to Nonalcoholic Steatofibrosis. <i>Clinical Gastroenterology and Hepatology</i> , 2017 , 15, 1144-1147	6.9	16

291	Liver and Cardiovascular Damage in Patients With Lean Nonalcoholic Fatty Liver Disease, and Association With Visceral Obesity. <i>Clinical Gastroenterology and Hepatology</i> , 2017 , 15, 1604-1611.e1	6.9	83
290	Nutritional Approaches to Achieve Weight Loss in Nonalcoholic Fatty Liver Disease. 2017 , 8, 253-265		23
289	Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases. 2017 , 66, 1138-1153		508
288	Non-alcoholic fatty liver disease - histological scoring systems: a large cohort single-center, evaluation study. 2017 , 125, 962-973		26
287	Prognostic Value of Controlled Attenuation Parameter by Transient Elastography. 2017 , 112, 1812-1823		49
286	Altered expression of MALAT1 lncRNA in nonalcoholic steatohepatitis fibrosis regulates CXCL5 in hepatic stellate cells. 2017 , 190, 25-39.e21		66
285	Ability of Cytokeratin-18 Fragments and FIB-4 Index to Diagnose Overall and Mild Fibrosis Nonalcoholic Steatohepatitis in Japanese Nonalcoholic Fatty Liver Disease Patients. 2017 , 35, 521-530		10
284	Effect of two andrographolide derivatives on cellular and rodent models of non-alcoholic fatty liver disease. 2017 , 95, 402-411		18
283	Nonalcoholic steatofibrosis independently predicts mortality in nonalcoholic fatty liver disease. 2017 , 1, 421-428		72
282	Health and economic benefits of reducing sugar intake in the USA, including effects via non-alcoholic fatty liver disease: a microsimulation model. 2017 , 7, e013543		71
281	Wet Biomarker-Based Assessment of Steatosis, Inflammation, and Fibrosis in NAFLD. 2017 , 16, 308-316		
280	Nonalcoholic fatty liver disease: implications for cardiovascular risk. 2017 , 6, 62-72		7
279	High fasting insulin concentrations may be a pivotal predictor for the severity of hepatic fibrosis beyond the glycemic status in non-alcoholic fatty liver disease patients before development of diabetes mellitus. 2017 , 47, 983-990		2
278	Significance of non-alcoholic fatty liver disease in Crohn's disease: A retrospective cohort study. 2017 , 47, 872-881		10
277	Nonalcoholic Steatohepatitis. 2017 , 68, 85-98		74
276	Animal models of non-alcoholic fatty liver disease: current perspectives and recent advances. 2017 , 241, 36-44		183
275	The risk of transient postprandial oxyhypoglycemia in nonalcoholic fatty liver disease. 2017 , 52, 253-262		3
274	High-intensity interval training: a review of its impact on glucose control and cardiometabolic health. 2017 , 60, 7-23		100

273	The therapeutic landscape of non-alcoholic steatohepatitis. 2017 , 37, 634-647	26
272	Case report of diet-related improvements of non-alcoholic steatohepatitis evaluated by four consecutive liver biopsies. 2017 , 47, 480-484	1
271	Epigenetics in non-alcoholic fatty liver disease. 2017 , 54, 78-88	73
270	Nonalcoholic Fatty Liver Disease. 2017 , 867-908	1
269	Serum thymosin beta4 as a noninvasive biomarker in patients with nonalcoholic steatohepatitis. 2018 , 110, 19-24	1
268	Nonalcoholic fatty liver disease: Diagnostic biomarkers. 2017 , 8, 11-26	57
267	The Role of Lipid and Lipoprotein Metabolism in Non-Alcoholic Fatty Liver Disease. 2017 , 4,	49
266	Prevalence and determinants of non-alcoholic fatty liver disease in lifelines: A large Dutch population cohort. 2017 , 12, e0171502	54
265	Serum metabolites in non-alcoholic fatty-liver disease development or reversion; a targeted metabolomic approach within the PREDIMED trial. 2017 , 14, 58	17
264	Clinical epidemiology and disease burden of nonalcoholic fatty liver disease. 2017 , 23, 8263-8276	316
263	Hepatocellular carcinoma in non-alcoholic steatohepatitis: Current knowledge and implications for management. 2017 , 9, 533-543	97
262	Combination of Ledipasvir and Sofosbuvir for Treatment of Hepatitis C Virus Genotype 1 Infection: Systematic Review and Meta-Analysis. 2017 , 16, 188-197	30
261	Nonalcoholic Fatty Liver Disease and Mortality. <i>Clinical Gastroenterology and Hepatology</i> , 2018 , 16, 1043-1045	7
260	The genetic backgrounds in nonalcoholic fatty liver disease. 2018 , 11, 97-102	27
259	Non-alcoholic steatofibrosis (NASF) can independently predict mortality in patients with non-alcoholic fatty liver disease (NAFLD). 2018 , 5, e000198	20
258	Diabetes impacts prediction of cirrhosis and prognosis by non-invasive fibrosis models in non-alcoholic fatty liver disease. 2018 , 38, 1793-1802	47
257	Consensus document. Management of non-alcoholic fatty liver disease (NAFLD). Clinical practice guideline. 2018 , 41, 328-349	30
256	Nonalcoholic fatty liver disease is an increasing indication for liver transplantation in the Nordic countries. 2018 , 38, 2082-2090	24

255	Low-Dose d-Amphetamine Induced Regression of Liver Fat Deposits in Dercum Disease. 2018 , 131, 705-708	6
254	The Natural History of Nonalcoholic Fatty Liver Disease-An Evolving View. 2018 , 22, 11-21	121
253	The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. 2018 , 67, 328-357	2641
252	Absorption, Distribution, Metabolism, and Excretion of [C]-Volixibat in Healthy Men: Phase 1 Open-Label Study. 2018 , 43, 91-101	8
251	Racial and Ethnic Disparities in Nonalcoholic Fatty Liver Disease Prevalence, Severity, and Outcomes in the United States: A Systematic Review and Meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2018 , 16, 198-210.e2	6.9 143
250	Clinical and Economic Burden of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. 2018 , 22, 1-10	56
249	The Role of Nonalcoholic Fatty Liver Disease on Cardiovascular Manifestations and Outcomes. 2018 , 22, 141-174	13
248	Clinical implications of controlled attenuation parameter in a health check-up cohort. 2018 , 38, 915-923	9
247	Association of non-alcoholic steatohepatitis with subclinical myocardial dysfunction in non-cirrhotic patients. 2018 , 68, 764-772	55
246	Clinical strategy of diagnosing and following patients with nonalcoholic fatty liver disease based on invasive and noninvasive methods. 2018 , 53, 181-196	46
245	Non-invasive assessment of non-alcoholic fatty liver disease: Clinical prediction rules and blood-based biomarkers. 2018 , 68, 305-315	241
244	Hypertension, diabetes, atherosclerosis and NASH: Cause or consequence?. 2018 , 68, 335-352	298
243	Should we undertake surveillance for HCC in patients with NAFLD?. 2018 , 68, 326-334	93
242	Alogliptin alleviates hepatic steatosis in a mouse model of nonalcoholic fatty liver disease by promoting CPT1a expression via Thr172 phosphorylation of AMPK α in the liver. 2018 , 17, 6840-6846	7
241	Metabolic Risk Factors in Hepatocellular Carcinoma. 2018 ,	1
240	Effect of a high-protein diet with Eryptoxanthin supplementation on metabolic risk factors, oxidative and inflammatory biomarkers in non-alcoholic fatty liver disease (NAFLD): study protocol for a randomized controlled clinical trial. 2018 , 19, 634	1
239	Ipragliflozin Ameliorates Liver Damage in Non-alcoholic Fatty Liver Disease. 2018 , 13, 402-409	25
238	The Impact of Metabolic Syndrome on the Outcome of NASH: Cirrhosis, Hepatocellular Carcinoma, and Mortality. 2018 , 17, 336-344	0

237	Cell-Free Circulating Nucleic Acids as Early Biomarkers for NAFLD and NAFLD-Associated Disorders. 2018 , 9, 1256	19
236	Developmental Exposure to 2,2',4,4'-Tetrabromodiphenyl Ether Permanently Alters Blood-Liver Balance of Lipids in Male Mice. 2018 , 9, 548	18
235	Characterization of spontaneously-developed non-alcoholic fatty liver disease in aged rhesus monkeys. 2018 , 10, 68	3
234	Non-alcoholic steatohepatitis-like pattern in liver biopsy of rheumatoid arthritis patients with persistent transaminitis during low-dose methotrexate treatment. 2018 , 13, e0203084	19
233	NAFLD and cardiovascular disease. 2018 , 3, e2	2
232	Consensus document. Management of non-alcoholic fatty liver disease (NAFLD). Clinical practice guideline. 2018 , 41, 328-349	1
231	Inhibitory effect of blue honeysuckle extract on high-fat-diet-induced fatty liver in mice. 2018 , 4, 288-293	16
230	Fibrosis Severity as a Determinant of Cause-Specific Mortality in Patients With Advanced Nonalcoholic Fatty Liver Disease: A Multi-National Cohort Study. 2018 , 155, 443-457.e17	308
229	Animal Models of Non-alcoholic Fatty Liver Diseases and Its Associated Liver Cancer. 2018 , 1061, 139-147	6
228	Epidemiology and Etiologic Associations of Non-alcoholic Fatty Liver Disease and Associated HCC. 2018 , 1061, 3-18	15
227	Obesity, Fatty Liver and Liver Cancer. 2018 ,	3
226	Non-alcoholic fatty liver disease-associated hepatocellular carcinoma: effect of hepatic steatosis on major hepatocellular carcinoma features at MRI. 2018 , 91, 20180345	14
225	Mechanistic Potential and Therapeutic Implications of Cannabinoids in Nonalcoholic Fatty Liver Disease. 2018 , 5,	12
224	Nonalcoholic Fatty Liver Disease in Children: Not a Small Matter. 2018 , 20, 315-329	16
223	The novel cutoff points for the FIB4 index categorized by age increase the diagnostic accuracy in NAFLD: a multi-center study. 2018 , 53, 1216-1224	37
222	Epigenetics: An emerging field in the pathogenesis of nonalcoholic fatty liver disease. 2018 , 778, 1-12	7
221	miRNAs in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis. 2018 , 69, 1335-1348	73
220	Effect of Alcohol Consumption on Survival in Nonalcoholic Fatty Liver Disease: A National Prospective Cohort Study. 2019 , 70, 511-521	51

219	Magnitude of Nonalcoholic Fatty Liver Disease: Western Perspective. 2019 , 9, 497-505	11
218	Altered bile acid composition and disposition in a mouse model of non-alcoholic steatohepatitis. 2019 , 379, 114664	24
217	The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis. 2019 , 71, 793-801	518
216	Potential Therapeutic Application of Estrogen in Gender Disparity of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis. 2019 , 8,	25
215	[Overview of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis Management]. 2019 , 139, 1147-1153	2
214	Green tea extract inhibits early oncogenic responses in mice with nonalcoholic steatohepatitis. 2019 , 10, 6351-6361	11
213	Lipid accumulation impairs lysosomal acid lipase activity in hepatocytes: Evidence in NAFLD patients and cell cultures. 2019 , 1864, 158523	12
212	Liver DNA methylation of FADS2 associates with FADS2 genotype. 2019 , 11, 10	12
211	The Mexican consensus on nonalcoholic fatty liver disease. 2019 , 84, 69-99	15
210	MALAT1 as a Diagnostic and Therapeutic Target in Diabetes-Related Complications: A Promising Long-Noncoding RNA. 2019 , 16, 548-555	43
209	Blond and blood juice supplementation in high fat diet fed mice: effect on antioxidant status and DDAH/ADMA pathway.. 2019 , 9, 11406-11412	1
208	Prevalence and long-term outcomes of non-alcoholic fatty liver disease among elderly individuals from the United States. 2019 , 19, 56	31
207	Extremely low levels of low-density lipoprotein potentially suggestive of familial hypobetalipoproteinemia: A separate phenotype of NAFLD?. 2019 , 13, 425-431	8
206	Serum C16:1n7/C16:0 ratio as a diagnostic marker for non-alcoholic steatohepatitis. 2019 , 34, 1829-1835	8
205	The Mexican consensus on nonalcoholic fatty liver disease. 2019 , 84, 69-99	1
204	Non-alcoholic fatty liver disease presence and severity are associated with aortic stiffness beyond abdominal obesity: The ELSA-Brasil. 2019 , 284, 59-65	10
203	Extra-hepatic manifestations and complications of nonalcoholic fatty liver disease. 2019 , 11, 2171-2192	18
202	Multi-technique comparison of atherogenic and MCD NASH models highlights changes in sphingolipid metabolism. 2019 , 9, 16810	17

201	Alcoholic and Nonalcoholic Fatty Liver Disease and Liver-Related Mortality: A Cohort Study. 2019 , 114, 620-629	29
200	Nonalcoholic fatty liver disease represents a greater metabolic burden in patients with atherosclerosis: A cross-sectional study. 2019 , 98, e14896	5
199	Impact of Non-Alcoholic Fatty Liver Disease on Cardiovascular Outcomes in Patients With Stable Coronary Artery Disease: A Matched Case-Control Study. 2019 , 10, e00011	12
198	Nonalcoholic Fatty Liver Disease: Identification and Management of High-Risk Patients. 2019 , 114, 579-590	14
197	Insulin-like growth factor-1 is inversely associated with liver fibrotic markers in patients with type 2 diabetes mellitus. 2019 , 10, 1083-1091	4
196	Crosstalk between nonalcoholic fatty liver disease and cardiometabolic syndrome. 2019 , 20, 599-611	38
195	A Sensing Peak Identification Method for Fiber Extrinsic Fabry? Perot Interferometric Refractive Index Sensing. 2018 , 19,	7
194	Rapid Recapitulation of Nonalcoholic Steatohepatitis upon Loss of Host Cell Factor 1 Function in Mouse Hepatocytes. 2019 , 39,	5
193	Lifestyle interventions for non-alcoholic fatty liver disease. 2019 , 26, 1519-1524	9
192	Chronic kidney disease is independently associated with increased mortality in patients with nonalcoholic fatty liver disease. 2019 , 39, 342-352	23
191	Clinical Epidemiology of Chronic Liver Diseases. 2019 ,	1
190	Predictors of nonalcoholic steatohepatitis and significant fibrosis in non-obese nonalcoholic fatty liver disease. 2019 , 39, 332-341	27
189	NonInvasive Biomarkers in Nonalcoholic Fatty Liver Disease: Are We There Yet?. 2020 , 10, 88-98	8
188	Natural History of Simple Steatosis or Nonalcoholic Fatty Liver. 2020 , 10, 255-262	18
187	Natural History of Non-Alcoholic Fatty Liver Disease: A Study With Paired Liver Biopsies. 2020 , 10, 245-254	9
186	Association between advanced fibrosis in fatty liver disease and overall mortality based on body fat distribution. 2020 , 35, 90-96	4
185	Nonalcoholic Steatohepatitis Is Associated With Liver-Related Outcomes and All-Cause Mortality in Chronic Hepatitis B. 2020 , 71, 539-548	51
184	Extra-Hepatic Manifestations of Nonalcoholic Fatty Liver Disease: A Review. 2020 , 10, 81-87	14

183	Metabolic syndrome, but not non-alcoholic fatty liver disease, increases 10-year mortality: A prospective, community-cohort study. 2020 , 40, 101-106	12
182	How to Identify the Patient with Nonalcoholic Steatohepatitis Who Will Progress to Cirrhosis. 2020 , 49, 45-62	2
181	Amitriptyline inhibits nonalcoholic steatohepatitis and atherosclerosis induced by high-fat diet and LPS through modulation of sphingolipid metabolism. 2020 , 318, E131-E144	8
180	Fructose-mediated effects on gene expression and epigenetic mechanisms associated with NAFLD pathogenesis. 2020 , 77, 2079-2090	26
179	The association of genetic polymorphisms with nonalcoholic fatty liver disease in a longitudinal study. 2020 , 20, 344	2
178	Hepatic lipid droplets: A balancing act between energy storage and metabolic dysfunction in NAFLD. 2021 , 50, 101115	33
177	NAFLD and NASH in Postmenopausal Women: Implications for Diagnosis and Treatment. 2020 , 161,	23
176	Progression of Fatty Liver Disease in Children Receiving Standard of Care Lifestyle Advice. 2020 , 159, 1731-1751.e10	17
175	High-Risk Groups for Non-alcoholic Fatty Liver and Non-alcoholic Steatohepatitis Development and Progression. 2020 , 19, 412-419	4
174	Validating candidate biomarkers for different stages of non-alcoholic fatty liver disease. 2020 , 99, e21463	0
173	New Perspectives on Genetic Prediction for Pediatric Metabolic Associated Fatty Liver Disease. 2020 , 8, 603654	9
172	Non-invasive predictors of prognosis of Asian patients with histopathologically-confirmed lean nonalcoholic fatty liver disease. 2020 , 20, 368	2
171	MRI-determined liver fat correlates with risk of metabolic syndrome in patients with nonalcoholic fatty liver disease. 2020 , 32, 754-761	3
170	Similar prevalence of hepatic steatosis among patients with chronic hepatitis C with and without HIV coinfection. 2020 , 10, 6736	2
169	Influence of increased physical activity without body weight loss on hepatic inflammation in patients with nonalcoholic fatty liver disease. 2020 , 25, 18	5
168	Non-alcoholic steatohepatitis and progression of carotid atherosclerosis in patients with type 2 diabetes: a Korean cohort study. 2020 , 19, 81	11
167	Portal inflammation predicts renal dysfunction in patients with nonalcoholic fatty liver disease. 2020 , 14, 798-807	3
166	Heightened Plasma Levels of Transforming Growth Factor Beta (TGF- β) and Increased Degree of Systemic Biochemical Perturbation Characterizes Hepatic Steatosis in Overweight Pediatric Patients: A Cross-Sectional Study. 2020 , 12,	4

165	Bacterial antigen translocation and age as BMI-independent contributing factors on systemic inflammation in NAFLD patients. 2020 , 40, 2182-2193	6
164	Epigallocatechin gallate but not catechin prevents nonalcoholic steatohepatitis in mice similar to green tea extract while differentially affecting the gut microbiota. 2020 , 84, 108455	24
163	Nonalcoholic fatty liver disease and cardiovascular disease phenotypes. 2020 , 8, 2050312120933804	3
162	Risk factors for hepatocellular carcinoma (HCC) in the northeast of the United States: results of a case-control study. 2020 , 31, 321-332	10
161	Current management of non-alcoholic steatohepatitis. 2020 , 40 Suppl 1, 89-95	24
160	Burden of Disease due to Nonalcoholic Fatty Liver Disease. 2020 , 49, 1-23	22
159	Nonalcoholic Fatty Liver Disease 2020: The State of the Disease. 2020 , 158, 1851-1864	238
158	Genetics of Non-Alcoholic Fatty Liver and Cardiovascular Disease: Implications for Therapy?. 2019 , 10, 1413	11
157	Tri-antennary tri-sialylated mono-fucosylated glycan of alpha-1 antitrypsin as a non-invasive biomarker for non-alcoholic steatohepatitis: a novel glycobiomarker for non-alcoholic steatohepatitis. 2020 , 10, 321	11
156	Natural History of Nonalcoholic Fatty Liver Disease: Implications for Clinical Practice and an Individualized Approach. 2020 , 2020, 9181368	20
155	Complications, morbidity and mortality of nonalcoholic fatty liver disease. 2020 , 111S, 154170	113
154	Differentially expressed mRNAs and lncRNAs shared between activated human hepatic stellate cells and nash fibrosis. 2020 , 22, 100753	5
153	Diagnosis of Non-Alcoholic Fatty Liver Disease (NAFLD) Is Independently Associated with Cardiovascular Risk in a Large Austrian Screening Cohort. 2020 , 9,	14
152	Women Have a Lower Risk of Nonalcoholic Fatty Liver Disease but a Higher Risk of Progression vs Men: A Systematic Review and Meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2021 , 19, 61-71.e13	58
151	ABIDE: An Accurate Predictive Model of Liver Decompensation in Patients With Nonalcoholic Fatty Liver-Related Cirrhosis. 2021 , 73, 2238-2250	7
150	Oscillating lncRNA regulates inflammasome to ameliorate nonalcoholic steatohepatitis in mice. 2021 , 11, 426-444	7
149	Childhood and Adolescent Obesity: A Review. 2020 , 8, 581461	35
148	Impact of Obesity in Non-Alcoholic Fatty Liver Disease. 2021 , 14, 21-32	1

147	Bariatric surgery in transplant recipients: A narrative review. 2021 , 26, 44	0
146	Acute and Chronic Hepatitis. 2021 , 819-837.e6	1
145	Cognitive Dysfunction in Non-Alcoholic Fatty Liver Disease-Current Knowledge, Mechanisms and Perspectives. 2021 , 10,	11
144	Therapy for Nonalcoholic Fatty Liver Disease: Current Options and Future Directions. 2021 , 43, 500-517	4
143	Progression of Nonalcoholic Fatty Liver Disease-Associated Fibrosis in a Large Cohort of Patients with Type 2 Diabetes. 2021 , 1	2
142	Simple non-invasive scoring systems and histological scores in predicting mortality in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis. 2021 , 36, 1754-1768	2
141	Comparison of dapagliflozin and teneligliptin in nonalcoholic fatty liver disease patients without type 2 diabetes mellitus: a prospective randomized study. 2021 , 68, 173-180	3
140	Treatment Candidacy for Pharmacologic Therapies for NASH. <i>Clinical Gastroenterology and Hepatology</i> , 2021 ,	6.9 6
139	Role of 2-series prostaglandins in the pathogenesis of type 2 diabetes mellitus and non-alcoholic fatty liver disease (Review). 2021 , 47,	4
138	Interplay between Heart Disease and Metabolic Steatosis: A Contemporary Perspective. 2021 , 10,	2
137	Normal tissue adjacent to tumor expression profile analysis developed and validated a prognostic model based on Hippo-related genes in hepatocellular carcinoma. 2021 , 10, 3139-3152	3
136	Update on cardiovascular risk in nonalcoholic fatty liver disease. 2021 , 36, 478-486	0
135	Expert Opinion on the Management of Non-Alcoholic Fatty Liver Disease (NAFLD) in the Middle East with a Focus on the Use of Silymarin. 2021 , 12, 155-165	4
134	Active p38 β causes macrovesicular fatty liver in mice. 2021 , 118,	2
133	Longitudinal Effect of Hemoglobin Concentration With Incident Ischemic Heart Disease According to Hepatic Steatosis Status Among Koreans. 2021 , 8, 677040	1
132	Progression from Nonalcoholic Fatty Liver to Nonalcoholic Steatohepatitis Cirrhosis Confirmed by Liver Histology after 14 Years. 2021 , 60, 1397-1401	1
131	Disease Knowledge, Health-Related Quality of Life, and Lifestyle Behavior Change in Patients with Nonalcoholic Fatty Liver Disease: Impact of an Educational Intervention. 2021 , 1	1
130	Mechanisms and disease consequences of nonalcoholic fatty liver disease. 2021 , 184, 2537-2564	132

129	The global epidemiology of nonalcoholic steatohepatitis (NASH) and associated risk factors: A targeted literature review. 2021 , 3, 100089	9
128	GDF11 rapidly increases lipid accumulation in liver cancer cells through ALK5-dependent signaling. 2021 , 1866, 158920	2
127	Links between metabolic syndrome and metabolic dysfunction-associated fatty liver disease. 2021 , 32, 500-514	24
126	Long Noncoding RNAs and Human Liver Disease. 2021 ,	3
125	Periodontal disease-related nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: An emerging concept of oral-liver axis. 2021 , 87, 204-240	10
124	The Obscure Effect of Saponins Plus Inulin on Liver Morphology, Liver Fatty Acids, Plasma Glucose, and Lipid Profile in SD Rats with and without Induced Type 2 Diabetes Mellitus. 2021 , 22,	3
123	Modelling human liver fibrosis in the context of non-alcoholic steatohepatitis using a microphysiological system. 2021 , 4, 1080	3
122	Cross-talk between non-alcoholic fatty liver disease and cardiovascular disease: Implications for future trial design. 2021 , 48, 101281	0
121	Non-alcoholic fatty liver disease and hematologic manifestations (Review). 2021 , 22, 1355	
120	A clinical overview of non-alcoholic fatty liver disease: A guide to diagnosis, the clinical features, and complications-What the non-specialist needs to know. 2021 ,	12
119	Nonalcoholic fatty liver disease, diastolic dysfunction, and impaired myocardial glucose uptake in patients with type 2 diabetes. 2021 , 23, 1041-1051	1
118	Nonalcoholic Fatty Liver Disease in Adults: The Impact of Diet and Other Therapeutic Interventions on Clinical and Histological Outcomes. 2013 , 61-73	1
117	Clinical Applications of Liver Magnetic Resonance Elastography: Chronic Liver Disease. 2014 , 39-60	1
116	Changing Epidemiology of Hepatocellular Carcinoma and Role of Surveillance. 2019 , 53-67	3
115	Clinical Epidemiology of NAFLD. 2019 , 211-227	2
114	Therapeutic opportunities for alcoholic steatohepatitis and nonalcoholic steatohepatitis: exploiting similarities and differences in pathogenesis. 2017 , 2,	30
113	Recent advances in understanding/management of non-alcoholic steatohepatitis. 2015 , 7, 28	7
112	Decreased circulating endothelial progenitor cell levels and function in patients with nonalcoholic fatty liver disease. 2012 , 7, e31799	33

111	Association between noninvasive fibrosis markers and chronic kidney disease among adults with nonalcoholic fatty liver disease. 2014 , 9, e88569	33
110	Circulating level of CTRP1 in patients with nonalcoholic fatty liver disease (NAFLD): is it through insulin resistance?. 2015 , 10, e0118650	25
109	Nonalcoholic Fatty Liver Disease: Correlation of the Liver Parenchyma Fatty Acid with Intravoxel Incoherent Motion MR Imaging-An Experimental Study in a Rat Model. 2015 , 10, e0139874	3
108	Insulin resistance in lean and overweight non-diabetic Caucasian adults: Study of its relationship with liver triglyceride content, waist circumference and BMI. 2018 , 13, e0192663	21
107	Nineteen-year prognosis in Japanese patients with biopsy-proven nonalcoholic fatty liver disease: Lean versus overweight patients. 2020 , 15, e0241770	7
106	Hepatocellular Carcinoma in Non-alcoholic Fatty Liver Disease: Epidemiology, Pathogenesis, and Prevention. 2013 , 1, 131-7	38
105	Nonalcoholic Fatty Liver Disease: Dyslipidemia, Risk for Cardiovascular Complications, and Treatment Strategy. 2015 , 3, 78-84	59
104	Current Modalities of Fibrosis Assessment in Non-alcoholic Fatty Liver Disease. 2017 , 5, 261-271	30
103	Non-alcoholic Fatty Liver Disease: Growing Burden, Adverse Outcomes and Associations. 2020 , 8, 76-86	39
102	The Role of Non-alcoholic Fatty Liver Disease in Cardiovascular Disease. 2014 , 9, 10-15	6
101	PERIPHERAL BLOOD ENDOTOXIN LEVELS ARE NOT ASSOCIATED WITH SMALL INTESTINAL BACTERIAL OVERGROWTH IN NONALCOHOLIC FATTY LIVER DISEASE WITHOUT CIRRHOSIS. 2020 , 57, 471-476	3
100	[Nonalcoholic fatty liver disease: What do we know and what will we have to learn?]. 2017 , 89, 91-98	1
99	GDF11 induces mild hepatic fibrosis independent of metabolic health. 2020 , 12, 20024-20046	6
98	JSH Consensus Kobe 2009; Diagnosis and Treatment of NASH. 2009 , 50, 741-747	8
97	Noninvasive predictors of nonalcoholic steatohepatitis in Korean patients with histologically proven nonalcoholic fatty liver disease. 2013 , 19, 120-30	19
96	KASL clinical practice guidelines: management of nonalcoholic fatty liver disease. 2013 , 19, 325-48	88
95	Pediatric nonalcoholic fatty liver disease, metabolic syndrome and cardiovascular risk. 2011 , 17, 3082-91	89
94	Nonalcoholic fatty liver disease: updates in noninvasive diagnosis and correlation with cardiovascular disease. 2014 , 20, 7718-29	24

93	Role of liver biopsy in nonalcoholic fatty liver disease. 2014 , 20, 9026-37	104
92	Simple scoring system for predicting cirrhosis in nonalcoholic fatty liver disease. 2014 , 20, 10108-14	16
91	Liver transplantation and non-alcoholic fatty liver disease. 2014 , 20, 15532-8	111
90	Correlation between non-alcoholic fatty liver with metabolic risk factors and brachial-ankle pulse wave velocity. 2015 , 21, 10192-9	8
89	Chemoprevention of obesity-related liver carcinogenesis by using pharmaceutical and nutraceutical agents. 2016 , 22, 394-406	10
88	Obese children with fatty liver: Between reality and disease mongering. 2017 , 23, 8277-8282	6
87	Promoting genetics in non-alcoholic fatty liver disease: Combined risk score through polymorphisms and clinical variables. 2018 , 24, 4835-4845	24
86	Noninvasive Evaluation of Nonalcoholic Fatty Liver Disease. 2020 , 35, 243-259	5
85	Nonalcoholic Fatty Liver Disease: A Drug Revolution Is Coming. 2020 , 44, 640-657	7
84	Adverse Effects of Sedentary Lifestyles: Inflammation, and High-Glucose Induced Oxidative Stress: A Double Blind Randomized Clinical Trial on Diabetic and Prediabetic Patients. 2020 , 12, 1029-1048	2
83	Current status and agenda in the diagnosis of nonalcoholic steatohepatitis in Japan. 2010 , 2, 374-83	13
82	Pediatric nonalcoholic fatty liver disease: A clinical and laboratory challenge. 2010 , 2, 275-88	36
81	Rapid chromatographic method to decipher distinct alterations in lipid classes in NAFLD/NASH. 2013 , 5, 558-67	20
80	Transitions of histopathologic criteria for diagnosis of nonalcoholic fatty liver disease during the last three decades. 2014 , 6, 894-900	12
79	Obesity and non-alcoholic fatty liver disease: Disparate associations among Asian populations. 2014 , 6, 263-73	78
78	Non-alcoholic fatty liver disease - the heart of the matter. 2015 , 7, 1369-76	35
77	Cardiovascular assessment in liver transplant for non-alcoholic steatohepatitis patients: What we do, what we should do. 2017 , 9, 697-703	8
76	Genetic Polymorphisms of PNPLA3 and SAMM50 Are Associated with Nonalcoholic Fatty Liver Disease in a Korean Population. 2018 , 12, 316-323	31

75	Characteristic Features of Nonalcoholic Fatty Liver Disease in Japan with a Focus on the Roles of Age, Sex and Body Mass Index. 2020 , 14, 537-545	15
74	Sarcopenia Is Significantly Associated with Presence and Severity of Nonalcoholic Fatty Liver Disease. 2019 , 28, 129-138	18
73	Association of Non-alcoholic Fatty Liver Disease with Conduction Defects on Electrocardiogram. 2017 , 9, e1107	10
72	Non-Alcoholic Fatty Liver Disease Association with Cardiac Arrhythmias. 2017 , 9, e1165	8
71	Assessment of Portal Venous and Hepatic Artery Haemodynamic Variation in Non-Alcoholic Fatty Liver Disease (NAFLD) Patients. 2016 , 10, TC07-10	4
70	ACC inhibitor alone or co-administered with a DGAT2 inhibitor in patients with non-alcoholic fatty liver disease: two parallel, placebo-controlled, randomized phase 2a trials. 2021 , 27, 1836-1848	14
69	Community Socioeconomic Deprivation Predicts Nonalcoholic Steatohepatitis. 2021 ,	0
68	Noninvasive markers: a double-edged sword that stratifies nonalcoholic steatohepatitis. 2013 , 19, 116-9	
67	Alcohol in Non-Alcoholic Fatty Liver Disease: an Oxymoron or a New Standard of Care?. 234-247	
66	The Proteome in Neurodegenerative Diseases. 2013 , 99-134	
65	A Case of Inflammatory Hepatocellular Adenoma Complicated by Steatohepatitis. 2014 , 04, 121-129	
64	Syndr�me m�tabolique, st�atopathie h�patique non alcoolique (NASH) et carcinome h�patocellulaire : des liaisons bien dangereuses.... 2014 , 198, 1653-1664	
63	Mouse Models to Study the Effect of Natural Products on Obesity-Associated NAFLD/NASH. 2015 , 247-270	1
62	The Association of Low Free Testosterone with Histological Severity of Nonalcoholic Fatty Liver Disease in Japanese Men. 2015 , 2,	1
61	Non-alcoholic Fatty Liver Disease in Obesity. 2016 , 159-179	
60	Heart Disease and the Liver: Interactions Between the Heart and the Liver. 2016 , 179-202	
59	Hepatic and Extrahepatic Malignancies in NAFLD. 2016 , 271-290	
58	Effects of Non-Alcoholic Fatty Liver in Rats by Acer tagmentosum Maxim. Extract. 2016 , 29, 307-312	

- 57 Nonalcoholic Fatty Liver Disease. **2017**, 199-216
- 56 ASSOCIATION OF INTESTINAL AMOEBIASIS WITH NONALCOHOLIC FATTY LIVER DISEASE (NAFLD)- A CASE-CONTROL STUDY. **2017**, 4, 3577-3581 0
- 55 Epidemiology and Comorbidities. **2018**, 1-83
- 54 Epidemiology of Chronic Liver Disease in the United States. **2019**, 57-74
- 53 Genetic risk factors of cytotoxicity syndrome in the treatment of recrudescence of chronic cardiovascular diseases. **2018**, 76-82 1
- 52 Outcomes of Non-Alcoholic Steatohepatitis Patients After Liver Transplantation: A Systematic Review and Meta-Analysis. **2019**, In Press,
- 51 Association of Non-Alcoholic Fatty Liver Disease with Increased Carotid Intima-Media Thickness Considering Other Cardiovascular Risk Factors. **2019**, 16, 0
- 50 The impact of scoring system in the evaluation of Nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). **2019**, 10, 262-266 1
- 49 Study of Non-Alcoholic Fatty Liver Disease and Its Association with Metabolic Syndrome. **2019**, 6, 3017-3021
- 48 Real Time Elastography is an Easy Tool for Diagnosis of Liver Fibrosis in Non-Alcoholic Fatty Liver Disease. **2020**, 10, 110-124
- 47 Hepatic Artery and Portal Vein Doppler Indexes in Non-alcoholic Fatty Liver Disease Before and After Treatment to Prevent Unnecessary Health Care Costs. **2014**, 5, 472-7 2
- 46 Controversies in the Diagnosis and Management of NAFLD and NASH. **2014**, 10, 219-27 24
- 45 Cardiovascular disorders in the context of non-alcoholic Fatty liver disease: a literature review. **2014**, 9, 1-8 3
- 44 Bariatric Surgery and Liver Transplantation. **2017**, 13, 170-175 2
- 43 Changes and roles of intestinal fungal microbiota in coronary heart disease complicated with nonalcoholic fatty liver disease. **2020**, 12, 3445-3460 2
- 42 Palmitate and Fructose Interact to Induce Human Hepatocytes to Produce Pro-Fibrotic Transcriptional Responses in Hepatic Stellate Cells Exposed to Conditioned Media. **2020**, 54, 1068-1082
- 41 Palmitate and Fructose Interact to Induce Human Hepatocytes to Produce Pro-Fibrotic Transcriptional Responses in Hepatic Stellate Cells Exposed to Conditioned Media. **2020**, 54, 1068-1082 1
- 40 Liver-related and extrahepatic events in patients with non-alcoholic fatty liver disease: a retrospective competing risks analysis.. **2022**, 2

39	Clinical Outcomes in Biopsy-Proven Nonalcoholic Fatty Liver Disease Patients: A Multicenter Registry-Based Cohort Study.. <i>Clinical Gastroenterology and Hepatology</i> , 2022 ,	6.9	2
38	Metabolic Syndrome Severity Predicts Mortality in Nonalcoholic Fatty Liver Disease. 2022 , 1, 445-456		1
37	Metabolic Syndrome and Metabolic Dysfunction-Associated Fatty Liver Disease. 2022 , 159-177		
36	Towards harnessing the value of organokine crosstalk to predict the risk for cardiovascular disease in non-alcoholic fatty liver disease.. 2022 , 130, 155179		0
35	Non-alcoholic fatty liver disease as an independent factor of cardiometabolic risk of cardiovascular diseases. 2021 , 22-34		
34	Table_1.XLSX. 2018 ,		
33	Table_2.XLSX. 2018 ,		
32	Table_3.XLSX. 2018 ,		
31	Comprehensive Review and Updates on Holistic Approach Towards Non-Alcoholic Fatty Liver Disease Management with Cardiovascular Disease.. 2022 ,		2
30	Medical checkup data analysis method based on LINGAM and its application to nonalcoholic fatty liver disease.. 2022 , 128, 102310		0
29	Non-alcoholic Fatty Liver Disease: Current Global Burden.		1
28	Association of serum and fecal bile acid patterns with liver fibrosis in biopsy-proven nonalcoholic fatty liver disease: An observational study. 2022 , Publish Ahead of Print,		0
27	Metabolic Dysfunction-Associated Fatty Liver Disease Is Associated with the Risk of Incident Cardiovascular Disease: A Prospective Cohort Study in Xinjiang. 2022 , 14, 2361		0
26	An improved method for isolation and flow cytometric characterization of intrahepatic leukocytes from fatty and fibrotic liver tissues.		1
25	European guideline on obesity care in patients with gastrointestinal and liver diseases □Joint ESPEN/UEG guideline. 2022 ,		4
24	European guideline on obesity care in patients with gastrointestinal and liver diseases □Joint European Society for Clinical Nutrition and Metabolism / United European Gastroenterology guideline.		1
23	Non-Alcoholic Fatty Liver Disease and Steatohepatitis. 2022 ,		0
22	Hepatocellular carcinoma (HCC) in patients with Non-Alcoholic Fatty Liver Disease (NAFLD): screening, treatment and survival analysis in a Brazilian series. 2022 , 77, 100097		0

- 21 The Change in the Fibrosis-4 Index for the Assessment of Liver Fibrosis After Pancreaticoduodenectomy. **2022**, 51, 624-627 ○
- 20 Risk predictors of advanced hepatic fibrosis in patients with nonalcoholic fatty liver disease [A survey in a university hospital in Brazil. **2022**, ○
- 19 Endothelial dysfunction in patients with non-alcoholic fatty liver disease. **2022**, 45-53 ○
- 18 The additive effect of genetic and metabolic factors in the pathogenesis of nonalcoholic fatty liver disease. **2022**, 12, ○
- 17 Comprehensive Review of Cardiovascular Disease Risk in Nonalcoholic Fatty Liver Disease. **2022**, 9, 419 1
- 16 Noninvasive imaging biomarkers for liver steatosis in NAFLD: present and future. ○
- 15 Diagnostic accuracy of enhanced liver fibrosis test for nonalcoholic steatohepatitis-related fibrosis: MULTICENTER STUDY. ○
- 14 Nonalcoholic Fatty Liver Disease (NAFLD) is Independently Associated with Higher All-Cause and Cause-Specific Mortality. **2023**, ○
- 13 Non-alcoholic Steatohepatitis: Global Impact and Clinical Consequences. 74-83 ○
- 12 Diagnostic Performance Comparison Between Ultrasound Attenuation Measurements From Right and Left Hepatic Lobes for Steatosis Detection in Non-alcoholic Fatty Liver Disease. **2022**, ○
- 11 Quantitative MRI in cardiometabolic disease: From conventional cardiac and liver tissue mapping techniques to multi-parametric approaches. 9, ○
- 10 Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: pathophysiology and implications for cardiovascular disease. **2023**, 137-173 ○
- 9 Practical Guideline on Obesity care in patients with gastrointestinal and liver diseases [Joint ESPEN / UEG guideline. **2023**, ○
- 8 Periodontal treatment and microbiome-targeted therapy in management of periodontitis-related nonalcoholic fatty liver disease with oral and gut dysbiosis. 29, 967-996 ○
- 7 Non-Alcoholic Fatty Liver Disease [Changing the Prevalence of Liver Cancer?. 12-18 ○
- 6 Association between smoking cessation and non-alcoholic fatty liver disease using NAFLD liver fat score. 11, ○
- 5 The Inter-Organ Crosstalk Reveals an Inevitable Link between MAFLD and Extrahepatic Diseases. **2023**, 15, 1123 ○
- 4 Baseline hepatocyte ballooning is a risk factor for adverse events in patients with chronic hepatitis B complicated with nonalcoholic fatty liver disease. 15, 237-254 ○

- 3 Effects of additive interactions among obesity, visceral adiposity, and sarcopenia on nonalcoholic fatty liver disease. **2023**, 13, ○
- 2 Faecalibacterium prausnitzii prevents hepatic damage in a mouse model of NASH induced by a high-fructose high-fat diet. 14, ○
- 1 Polycystic ovary syndrome and nonalcoholic fatty liver disease. **2024**, 92-99 ○